Pyrls on Instagram: Brexpiprazole's (REXULTI) new indication makes it the first FDA-approved option for agitation associated with dementia due to Alzheimer's disease ✨ Learn more about brexpiprazole in your Pyrls app or

292 likes, 1 comments - pyrls no May 14, 2023: "Brexpiprazole's (REXULTI) new indication makes it the first FDA-approved option for agitation ass"

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® ( brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation

Rexulti Approved for Agitation Associated With Dementia Due to Alzheimer Disease

FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease

FDA OKs First Drug for Agitation in Alzheimer's Dementia

First FDA Approved Medication for Agitation Associated with Alzheimer's Dementia – Psychiatry Education Forum

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Brexpiprazole (Rexulti) Approved for Alzheimer's Agitation

Statement on the FDA Approval of Brexpiprazole

First FDA Approved Medication for Agitation Associated with Alzheimer's Dementia – Psychiatry Education Forum

First FDA Approved Medication for Agitation Associated with Alzheimer's Dementia – Psychiatry Education Forum